The tumor-to-blood ratio of 89Zr-DFO-CD8a was significantly lower in CD8a+ depleted mice compared to control mice (5.6 ± 0.03 vs. 8.3 ± 0.32, p=0.011, Figure 2E). This evidence concerns the gene CD8A and neoplasm.